Key result
Japan-specific rivaroxaban linked to ~36% higher target peak anti-Xa attainment vs standard doses in Thai patients.
Why the study?
Lower rivaroxaban doses are approved for SPAF in Japan, but it is unknown whether 15 and 10 mg/day doses are appropriate in other Asian populations.
Do Japan-specific doses of rivaroxaban achieve more appropriate anti-Factor Xa activity compared to standard doses in Thai patients with non-valvular atrial fibrillation?
Comparison
Standard doses (20/15 mg) vs Japan-specific doses (15/10 mg) stratified by renal function
Authors
Loading...
Japan-specific rivaroxaban dosing was associated with more expected peak anti-FXa activity in Thai NVAF patients; leaves open impact on clinical outcomes.
Observational (n=60)
Do Japan-specific doses of rivaroxaban achieve more appropriate anti-Factor Xa activity compared to standard doses in Thai patients with non-valvular atrial fibrillation?
Absolute Event Rate: 87.7% vs 64.4%
p-value: p=0.001
Japan-specific lower doses of rivaroxaban resulted in a significantly higher proportion of Thai patients achieving expected peak anti-FXa activity compared to standard doses.
Wongcharoen et al. (2020) conducted an observational in Non-valvular atrial fibrillation (n=60). Japan-specific dose of rivaroxaban vs. Standard dose of rivaroxaban (20 and 15 mg/day) was evaluated on Anti-Factor Xa activity at peak concentrations within the expected range (p=0.001). Japan-specific doses of rivaroxaban achieved peak anti-Factor Xa activity within the expected range in more Thai patients than standard doses (87.7% vs. 64.4%; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: